Companies › Cognition Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CT1812 sigma-2 receptor ligand | – | Phase 2 | Early Alzheimer's Disease | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05531656 | CT1812 | Phase 2 | Early Alzheimer's Disease | Neurology | May 2027 |
Cash of $31m on 2026-09-30; operating cash outflow about $16m a year; runway about 23 months at that burn, to Sep 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Satellos Bioscience Coya Therapeutics PepGen DiaMedica Therapeutics IGC Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.